SymBio Pharmaceuticals Limited (TYO:4582)
170.00
+10.00 (6.25%)
May 19, 2025, 3:30 PM JST
SymBio Pharmaceuticals Balance Sheet
Financials in millions JPY. Fiscal year is January - December.
Millions JPY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Cash & Equivalents | 3,614 | 3,963 | 6,517 | 6,282 | 3,860 | 3,849 | Upgrade
|
Cash & Short-Term Investments | 3,614 | 3,963 | 6,517 | 6,282 | 3,860 | 3,849 | Upgrade
|
Cash Growth | -44.78% | -39.19% | 3.74% | 62.74% | 0.30% | -1.59% | Upgrade
|
Accounts Receivable | 211 | 423 | 913 | 2,084 | 2,148 | 406.99 | Upgrade
|
Other Receivables | - | - | - | - | - | 314.76 | Upgrade
|
Receivables | 211 | 423 | 913 | 2,084 | 2,148 | 721.75 | Upgrade
|
Inventory | 256 | 238 | 232 | 469 | 385.68 | 944.92 | Upgrade
|
Prepaid Expenses | 137 | 110 | 119 | 209 | 145.01 | 80.65 | Upgrade
|
Other Current Assets | 410 | 190 | 301 | 268 | 209.53 | 219.35 | Upgrade
|
Total Current Assets | 4,628 | 4,924 | 8,082 | 9,312 | 6,748 | 5,815 | Upgrade
|
Property, Plant & Equipment | - | - | - | 69 | 83.64 | 76.7 | Upgrade
|
Long-Term Investments | 38 | 44 | 87 | 85 | - | - | Upgrade
|
Other Intangible Assets | - | - | - | 222 | 259.1 | 301.84 | Upgrade
|
Long-Term Deferred Tax Assets | 1 | - | - | 744 | 1,276 | - | Upgrade
|
Other Long-Term Assets | - | - | 1 | 1 | 86.66 | 80.87 | Upgrade
|
Total Assets | 4,667 | 4,968 | 8,170 | 10,433 | 8,453 | 6,275 | Upgrade
|
Accounts Payable | - | - | - | 46 | 69.68 | 665.46 | Upgrade
|
Accrued Expenses | - | - | - | - | 516.04 | - | Upgrade
|
Current Income Taxes Payable | 514 | 737 | 872 | 1,564 | 383.6 | 81.93 | Upgrade
|
Current Unearned Revenue | - | - | - | - | - | 192.71 | Upgrade
|
Other Current Liabilities | 50 | 29 | 84 | 313 | 548.79 | 675.25 | Upgrade
|
Total Current Liabilities | 564 | 766 | 956 | 1,923 | 1,518 | 1,615 | Upgrade
|
Long-Term Debt | 700 | - | - | - | - | - | Upgrade
|
Other Long-Term Liabilities | 2 | 3 | 1 | 2 | 186.44 | 0 | Upgrade
|
Total Liabilities | 1,270 | 773 | 960 | 1,928 | 1,707 | 1,617 | Upgrade
|
Common Stock | 18,588 | 18,336 | 17,952 | 17,548 | 17,158 | 17,045 | Upgrade
|
Additional Paid-In Capital | 18,562 | 18,311 | 17,927 | 17,523 | 17,133 | 17,019 | Upgrade
|
Retained Earnings | -34,006 | -32,685 | -28,852 | -26,889 | -27,978 | -30,010 | Upgrade
|
Treasury Stock | -89 | -89 | -89 | -88 | -86.05 | -17.54 | Upgrade
|
Comprehensive Income & Other | 342 | 322 | 272 | 411 | 519.1 | 620.14 | Upgrade
|
Shareholders' Equity | 3,397 | 4,195 | 7,210 | 8,505 | 6,746 | 4,657 | Upgrade
|
Total Liabilities & Equity | 4,667 | 4,968 | 8,170 | 10,433 | 8,453 | 6,275 | Upgrade
|
Total Debt | 700 | - | - | - | - | - | Upgrade
|
Net Cash (Debt) | 2,914 | 3,963 | 6,517 | 6,282 | 3,860 | 3,849 | Upgrade
|
Net Cash Growth | -55.48% | -39.19% | 3.74% | 62.74% | 0.30% | -1.59% | Upgrade
|
Net Cash Per Share | 63.16 | 87.88 | 163.32 | 158.62 | 99.38 | 116.80 | Upgrade
|
Filing Date Shares Outstanding | 47.27 | 47.83 | 44.75 | 39.52 | 38.37 | 38.17 | Upgrade
|
Total Common Shares Outstanding | 47.27 | 45.84 | 42.19 | 39.52 | 38.37 | 38.17 | Upgrade
|
Working Capital | 4,064 | 4,158 | 7,126 | 7,389 | 5,230 | 4,200 | Upgrade
|
Book Value Per Share | 71.86 | 91.52 | 170.89 | 215.22 | 175.78 | 122.01 | Upgrade
|
Tangible Book Value | 3,397 | 4,195 | 7,210 | 8,283 | 6,487 | 4,355 | Upgrade
|
Tangible Book Value Per Share | 71.86 | 91.52 | 170.89 | 209.60 | 169.03 | 114.10 | Upgrade
|
Buildings | - | - | - | - | 64.62 | 59.12 | Upgrade
|
Machinery | - | - | - | - | 72.73 | 90.04 | Upgrade
|
Updated Feb 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.